Inhibrx Biosciences holder plans sale of 500 shares

A trust associated with director Kimberly Manhard has filed a Rule 144 notice to sell 500 INBX common shares.

Rhea-AI Filing Summary

Inhibrx Biosciences, Inc. (INBX) received a Rule 144 notice relating to a proposed sale of its common stock. A person identified as Kimberly Manhard, through the Kimberly Joan Manhard Revocable Trust, has filed to sell 500 shares of Inhibrx Biosciences common stock through Fidelity Brokerage Services LLC.

Key Figures

Proposed shares to be sold: 500 shares Aggregate market value of securities to be sold: $57,897.50 Shares sold in past 3 months: 500 shares +2 more

5 metrics

Proposed shares to be sold 500 shares Common stock covered by the Rule 144 notice

Aggregate market value of securities to be sold $57,897.50 Value associated with the 500 INBX shares in the securities information section

Shares sold in past 3 months 500 shares INBX common stock sold by the Kimberly Joan Manhard Revoc Trust in the prior three months

Aggregate sale proceeds in past 3 months $57,570.00 Consideration received for 500 INBX shares sold in the past three months

Shares outstanding 14,717,660 shares INBX common stock outstanding as listed in the securities information section

Key Terms

Rule 144, Open Market Purchase, aggregate consideration, attorney-in-fact

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Open Market Purchase financial

"Common | 08/28/2024 | Open Market Purchase | Issuer"

An open market purchase is when a company buys its own shares on public stock exchanges the same way any investor would, rather than through a private deal. Investors care because these purchases reduce the number of shares available, can boost earnings per share and share price, signal that management thinks the stock is undervalued, and use company cash that might otherwise go to reinvestment or dividends — like a business quietly buying back its own tickets at the box office.

aggregate consideration financial

"Common | 09/08/2026 | 500 | 57570.00"

attorney-in-fact regulatory

"as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Kimberly Manhard."

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What does the Form 144 filing mean for Inhibrx Biosciences, Inc. (INBX)?

The filing reports a proposed sale of 500 common shares of Inhibrx Biosciences, Inc. by a person associated with director Kimberly Manhard under Rule 144. It is a notice of intended resale by an affiliate, not an issuance of new shares by the company.

How many INBX shares are proposed to be sold under this Form 144?

The notice covers a proposed sale of 500 shares of common stock of Inhibrx Biosciences, Inc. through Fidelity Brokerage Services LLC.

Who is the selling security holder in this INBX Form 144?

The securities are to be sold for the account of Kimberly Manhard, with the filing stating that today’s sale and sales in the past three months occurred in the Kimberly Joan Manhard Revoc Trust, of which she is a trustee.

What is the approximate market value of the INBX shares covered by this Form 144?

The filing lists 500 shares of INBX common stock with an aggregate market value of $57,897.50 in the securities information section.

Were any INBX shares sold by this filer in the past three months?

Yes. The Form 144 discloses that the Kimberly Joan Manhard Revoc Trust sold 500 shares of INBX common stock during the past three months for an aggregate consideration of $57,570.00.

How many Inhibrx Biosciences (INBX) shares are outstanding according to this notice?

The notice lists 14,717,660 shares of INBX common stock as outstanding, providing context for the size of the proposed 500-share sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 05:16 PM Accepted by SEC EDGAR 09/09/2026 - 05:15 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001202094
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Inhibrx Biosciences, Inc.
SEC File Number	001-42031
Address of Issuer	11025 N. TORREY PINES ROAD, SUITE 140 LA JOLLA CALIFORNIA 92037
Phone	(858) 795-4220
Name of Person for Whose Account the Securities are To Be Sold	MANHARD KIMBERLY
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	500	57897.50	14717660	09/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/28/2024	Open Market Purchase	Issuer			500	08/28/2024	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Kimberly Joan Manhard Revoc Trust 11025 N. Torrey Pines Road Suite 140 La Jolla CA 92037	Common	09/08/2026	500	57570.00

144: Remarks and Signature

Remarks	Today's sale and sales from the past 3 months occurred in the Kimberly Joan Manhard Revoc Trust of which Kimberly Manhard is a trustee.
Date of Notice	09/09/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Joshua Schmitt, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Kimberly Manhard.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)